Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

DIAN, Roche, Foundation in Chinese genomic profiling deal

May 4, 2018 5:34 PM UTC

Foundation Medicine Inc. (NASDAQ:FMI), DIAN Diagnostics Group Co. Ltd. (SZSE:300244) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to integrate Foundation Medicine's suite of genomic profiling (CGP) tests into clinical patient care in China. The tests include FoundationOne, FoundationACT and FoundationOne Heme.

Under the deal, DIAN will be the exclusive provider of sequencing services for the suite and Roche will commercialize the diagnostics in China. The pharma has rights to the tests under a 2015 deal (see BioCentury, Jan. 19, 2015)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article